Adcentrx Therapeutics Announces Completion of $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development

30 Apr, 2021

Adcentrx Therapeutics Announces Completion of $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development
Photo by Markus Winkler on Unsplash

– Adcentrx closed $50m Series A financing to power the development of next generation ADC for improving patient treatment options.
– This round of financing was led by CBC Group and Zoo Capital also joined this round.
– Adcentrx was founded by a veteran ADC team with extensive experience in ADC conjugation, target biology and CMC.
– The founder, Dr. Hui Li, was the CEO of Levena Biopharma, the ADC subsidiary of Sorrento Therapeutics.
– Dr. Pia Challita-Eid, head of research at Adcentrx, has led teams at Agensys, responsible for novel target and drug discovery.

Biotechnology North America
Crunchbase icon

Content report

The following text will be sent to our editors: